Premium
Long‐term follow‐up in dogs with idiopathic eosinophilic bronchopneumopathy treated with inhaled steroid therapy
Author(s) -
Cane A.M.,
Bolen G.,
Peeters D.,
Billen F.,
Clercx C.
Publication year - 2016
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/jsap.12529
Subject(s) - medicine , fluticasone , eosinophilic , corticosteroid , adverse effect , gastroenterology , anesthesia , pathology
BACKGROUND Treatment of canine idiopathic eosinophilic bronchopneumopathy mainly consists of long‐term oral corticosteroid therapy. To avoid side effects, inhaled steroid therapy has been increasingly used but long‐term clinical response and potential side effects are sparsely described. OBJECTIVES Description of clinical response and side effects with long‐term fluticasone in dogs with eosinophilic bronchopneumopathy. METHODS Case series of dogs with eosinophilic bronchopneumopathy and treated with fluticasone monotherapy for at least 6 months. Clinical response and side effects assessed by physical examination, standardised questionnaire and ACTH (corticotropin) stimulation test. RESULTS Eight dogs were treated for between 6 months and 5 years. Cough initially improved in all dogs; two dogs remained free of clinical signs, three were well controlled, but three showed severe relapse. Pituitary–adrenal axis inhibition occurred in two dogs treated with fluticasone monotherapy for more than 2 years; only one dog had clinical signs of iatrogenic hyperadrenocorticism. CLINICAL SIGNIFICANCE Fluticasone monotherapy allows initial improvement or remission in the majority of dogs but long‐term treatment fails to resolve the cough in some individuals. In addition, such therapy may induce pituitary‐adrenal axis inhibition. Prospective larger and randomised studies including both fluticasone and orally‐treated dogs are needed to define the optimal treatment.